2519.HK

AuGroup (Shenzhen) Cross-border Business Co. Ltd. (2519.HK), a cross-border e-commerce platform specializing in household products, launched its Hong Kong IPO on Thursday, aiming to sellnearly 30 million shares, with about 10% reserved for local investors. It set a price range of HK$14.56 to HK$15.60

Shares will sell in lots of 300, translating to an admission fee of HK$4,727.20 for investors. The listing could raise up to HK$470 million ($60 million). The public subscription period ends on Nov. 5, with a trading debut set for Nov. 8.

In 2021, the company was banned by American e-commerce giant Amazon for posting fake reviews to boost its sales.  The incident caused the company’s revenue to drop by 22% to 7.1 billion yuan in 2022, setting back its listing plan.

The company’s business has gradually picked up since then after it made adjustments. Last year’s revenue increased by 22% to 8.68 billion yuan, and the figure rose 17% year-on-year to 2.83 billion yuan in the first four months of this year.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click  here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…